Merck & Company Inc (MRK)vsOrganiGram Holdings Inc (OGI)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
OGI
OrganiGram Holdings Inc
$1.37
-2.14%
HEALTHCARE · Cap: $192.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23119% more annual revenue ($65.01B vs $279.99M). MRK leads profitability with a 28.1% profit margin vs 6.5%. OGI trades at a lower P/E of 12.4x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
OGI
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+84.7%
Fair Value
$8.54
Current Price
$1.37
$7.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 48.7% year-over-year
Attractively priced relative to earnings
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 4.6% — below average capital efficiency
6.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : OGI
The strongest argument for OGI centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 48.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while OGI is a hypergrowth play — different risk/reward profiles.
OGI carries more volatility with a beta of 1.87 — expect wider price swings.
OGI is growing revenue faster at 48.7% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 46/100), backed by strong 28.1% margins. OGI offers better value entry with a 84.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?